Thursday, Creative Medical Technology Holdings Inc (NASDAQ:CELZ) secured FDA authorization for an expanded access therapy using CELZ-201, a cell-based program to manage abnormal glucose tolerance and prevent Type 1 diabetes (T1D) in high-risk individuals.
The therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in medical history.
This personalized medicine approach focuses on a single high-risk patient.
CELZ-201 has a multi-target mechanism to address abnormal glucose tolerance, a T1D precursor, at the cellular level. It embodies hope for high-risk individuals, offering a proactive defense against T1D development.
The shares are trading on a higher session volume of 1.262 million compared to the average volume of 67.610K, as per the data from Benzinga Pro.
Wednesday, the FDA granted Orphan Drug Designation to Creative Medical's CELZ-101, ImmCelz, aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation, a significant advancement for individuals with Type 1 diabetes.
CELZ-101 represents an approach in personalized medicine, utilizing the patient's regulatory T cells (Tregs) to combat autoimmune and alloimmune responses that can destroy insulin-producing cells.
Price Action: CELZ shares are up 34.50% at $6.40 on the last check Thursday.
Photo by Towfiqu barbhuiya on Unsplash